ERBB2 and breast carcinoma: In addition, the phase III APHINITY study reported a 12% recurrence rate in HER2-positive breast cancer patients with node-positive disease after receiving 1 year of adjuvant trastuzumab, pertuzumab, and chemotherapy with a median follow-up of 74 months (Piccart et al., 2021).